These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27933686)

  • 21. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014.
    Ludvigsson JF; Mahl M; Sachs MC; Björk J; Michaelsson K; Ekbom A; Askling J; Backman AS; Olén O
    Am J Gastroenterol; 2019 Feb; 114(2):291-304. PubMed ID: 30730858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory bowel diseases in Faroese-born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development.
    Hammer T; Lophaven SN; Nielsen KR; von Euler-Chelpin M; Weihe P; Munkholm P; Burisch J; Lynge E
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1107-1114. PubMed ID: 28176348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study.
    Park S; Chun J; Han KD; Soh H; Choi K; Kim JH; Lee J; Lee C; Im JP; Kim JS
    World J Gastroenterol; 2018 Nov; 24(42):4798-4808. PubMed ID: 30479466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher Risk for Hematological Malignancies in Inflammatory Bowel Disease: A Nationwide Population-based Study in Taiwan.
    Wang LH; Yang YJ; Cheng WC; Wang WM; Lin SH; Shieh CC
    Am J Gastroenterol; 2016 Sep; 111(9):1313-9. PubMed ID: 27296944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy.
    Kim J; Im JP; Yim JJ; Lee CK; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Korean J Gastroenterol; 2020 Jan; 75(1):29-38. PubMed ID: 31986571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.
    Jeuring SFG; Biemans VBC; van den Heuvel TRA; Zeegers MP; Hameeteman WH; Romberg-Camps MJL; Oostenbrug LE; Masclee AAM; Jonkers DMAE; Pierik MJ
    Am J Gastroenterol; 2018 Mar; 113(3):384-395. PubMed ID: 29317770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease.
    Andersson P; Karling P
    Ups J Med Sci; 2022; 127():. PubMed ID: 35140875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Faroese IBD Study: Incidence of Inflammatory Bowel Diseases Across 54 Years of Population-based Data.
    Hammer T; Nielsen KR; Munkholm P; Burisch J; Lynge E
    J Crohns Colitis; 2016 Aug; 10(8):934-42. PubMed ID: 26933031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased risk of idiopathic pulmonary fibrosis in inflammatory bowel disease: A nationwide study.
    Kim J; Chun J; Lee C; Han K; Choi S; Lee J; Soh H; Choi K; Park S; Kang EA; Lee HJ; Im JP; Kim JS
    J Gastroenterol Hepatol; 2020 Feb; 35(2):249-255. PubMed ID: 31420894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.
    Lewis JD; Scott FI; Brensinger CM; Roy JA; Osterman MT; Mamtani R; Bewtra M; Chen L; Yun H; Xie F; Curtis JR
    Am J Gastroenterol; 2018 Mar; 113(3):405-417. PubMed ID: 29336432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
    Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
    J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
    Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.
    Bröms G; Granath F; Stephansson O; Kieler H
    Scand J Gastroenterol; 2016 Dec; 51(12):1462-1469. PubMed ID: 27739352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.
    Kang J; Jeong DH; Han M; Yang SK; Byeon JS; Ye BD; Park SH; Hwang SW; Shim TS; Jo KW
    J Korean Med Sci; 2018 Nov; 33(47):e292. PubMed ID: 30450023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study.
    Kim HJ; Hann HJ; Hong SN; Kim KH; Ahn IM; Song JY; Lee SH; Ahn HS
    Inflamm Bowel Dis; 2015 Mar; 21(3):623-30. PubMed ID: 25647154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications.
    Ban L; Tata LJ; Fiaschi L; Card T
    Gastroenterology; 2014 Jan; 146(1):76-84. PubMed ID: 24126096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of malignancy in a high-incidence population-based cohort of Faroese patients with inflammatory bowel disease from 1960 to 2020 - a Faroese IBD cohort study.
    Midjord J; Nielsen KR; Vang AG; Strøm M; Lophaven S; Hammer T; Burisch J
    Scand J Gastroenterol; 2024 Jun; 59(6):661-668. PubMed ID: 38407208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tuberculosis in an inflammatory bowel disease cohort from South Africa.
    Deetlefs E; Epstein D; Watermeyer GA; Seggie RM; Thomson SR
    S Afr Med J; 2012 Sep; 102(10):802-4. PubMed ID: 23034210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.